New Data Demonstrates Link Between Gout and Cardiovascular Disease
December 20th 2019Monosodium urate (MSU) deposits detected by dual-energy computed tomography (DECT) are common in patients with gout and are associated with higher coronary calcium scores, researchers recently reported in JAMA Cardiology.
Read More
Dapagliflozin Benefits Heart Failure Patients, With or Without Diabetes
October 9th 2019The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
Read More
Neither Linagliptin nor Glimepiride Increases Cardiovascular Risk in Diabetes
October 9th 2019Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.
Read More
linagliptin Safe for Diabetes Patients with Elevated Cardiovascular Risk
October 2nd 2019Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
Read More
Diabetes Drug Dapagliflozin Prevents Worsening Heart Failure, Study Shows
October 2nd 2019The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.
Read More